DRMANasdaqPharmaceutical PreparationsFiscal year ends December 31
Dermata Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$0.86−0.00 (-0.01%)
Close on Oct 19, 2026
- Market cap
- $3.46M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$3.1101 (−78.34%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $3.46M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.99
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$8.37M
- EPS, diluted
- -$4.52
- Book value per share
- $0.87
- Diluted shares
- 4M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Operating income
-$8.60M
Net income
-$8.37M
EPS, diluted
-$4.52
Reported periodTrailing twelve months